United States
Germany
FranceThe Power to Transform How Genetic Diseases are Treated
At Krystal, we are distinguished in three powerful ways – science and technology, rapid and reliable manufacturing, and a unique commercialization model that focuses on the patient experience. These three elements are dedicated to making redosable gene delivery a therapy that is both accessible and successful.
Technology Platform
Redosable gene therapy holds the potential to provide long-lasting disease correction in a way that can be adjusted to meet the needs of an individual patient, and Krystal’s HSV‑1‑based vector technology has unique capabilities for focal gene delivery to treat diseases with high unmet medical needs.
Pipeline
Krystal is at the forefront of developing gene delivery medicines. With a robust pipeline of development programs and an approved product, learn more Krystal’s pipeline of drug candidates.
Manufacturing
As experts in HSV-1 manufacturing, Krystal has two GMP manufacturing facilities to support commercial needs as well as pipeline development.
Therapeutic Areas
As first-in-class developers of a redosable gene delivery platform, Krystal has a strong pipeline of candidates targeting genetic indications with significant unmet medical needs.
Medical Professionals
Krystal is committed to supporting the healthcare community across disease areas, and Krystal engages with medical professionals to provide information about the company’s research, treatments in development, access to investigational medicines and more.
Discovering, developing, and commercializing genetic medicines with purpose
